Hypogonadism News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Secondary (Hypogonadotropic) Hypogonadism Market Therapeutic Pipeline Review H2 2017, Drug Profile and Major ... - Expert Herald



Expert Herald
 
Secondary (Hypogonadotropic) Hypogonadism Market Therapeutic Pipeline Review H2 2017, Drug Profile and Major ... 
Expert Herald
Secondary (Hypogonadotropic) Hypogonadism Market H2, latest research provides in depth analysis of Key players with pipeline review and targeted therapeutics covering drugs profile of Secondary (Hypogonadotropic) Hypogonadism industry.

 


Male Hypogonadism Market Pipeline Review H2 2017 Industry Research Toward a Cure, And Immune-Based and ... - Expert Herald



Expert Herald
 
Male Hypogonadism Market Pipeline Review H2 2017 Industry Research Toward a Cure, And Immune-Based and ... 
Expert Herald
Male Hypogonadism Market H2 2017, latest research provides in depth analysis of Key players with pipeline review and targeted therapeutics covering drugs profile of Male Hypogonadism industry. Male hypogonadism is a condition in which the body doesn't ...

 


Secondary {Hypogonadotropic} Hypogonadism ? Diseases & Therapeutic Pipeline Review, H2 2017 - Medgadget (blog)



Secondary {Hypogonadotropic} Hypogonadism ? Diseases & Therapeutic Pipeline Review, H2 2017 
Medgadget (blog)
A new independent 58 page research with title 'Secondary {Hypogonadotropic} Hypogonadism ? Pipeline Review, H2 2017? guarantees you will remain better informed than your competition. The study covers geographic analysis and important ...

 


Male Hypogonadism Market Driven by Escalating Geriatric Population - TMR Research Blog (press release) (blog)



TMR Research Blog (press release) (blog)
 
Male Hypogonadism Market Driven by Escalating Geriatric Population 
TMR Research Blog (press release) (blog)
San Francisco, California, October 31, 2017 : The awareness pertaining to the prevalence of hypogonadism and the availability of treatment options will ensure a prosperous future for the global male hypogonadism market, according to a recent commerce ...

and more » 


Male Hypogonadism Market Report to Gain the Best Competitive Advantage; Lucrative Portfolio - Medgadget (blog)



Male Hypogonadism Market Report to Gain the Best Competitive Advantage; Lucrative Portfolio 
Medgadget (blog)
?Male Hypogonadism-Mechanism of action Insights, 2017?, report provides comprehensive insights of the ongoing therapeutic research and development across Male Hypogonadism. The report provides a complete understanding of the pipeline activities ...

and more » 


Male Health Drug Market Outlook 2022: Top Companies, Trends and Future Prospects Details for Business Development - Expert Herald



Expert Herald
 
Male Health Drug Market Outlook 2022: Top Companies, Trends and Future Prospects Details for Business Development 
Expert Herald
Male hypogonadism is a condition in which the body doesn't produce enough testosterone, resulting in signs and symptoms of testosterone deficiency and/or infertility. Symptoms include fatigue, hot flashes, infertility, decrease in muscle mass and loss ...

 


US FDA Extends Review for TLANDO?; Advisory Committee Meeting Date of January 10, 2018 Remains Unchanged - Markets Insider



US FDA Extends Review for TLANDO?; Advisory Committee Meeting Date of January 10, 2018 Remains Unchanged 
Markets Insider
?We believe TLANDO addresses a significant unmet medical need for men with hypogonadism and we will continue to work closely with the FDA throughout the review process," said Dr. Mahesh Patel, Chairman, President and Chief Executive Officer of ...

and more » 


Testosterone Therapy May Lower Prostate Cancer Incidence - Renal and Urology News



Renal and Urology News
 
Testosterone Therapy May Lower Prostate Cancer Incidence 
Renal and Urology News
Hypogonadal men who receive testosterone replacement therapy (TRT) may have a lower incidence of prostate cancer (PCa) than those not receiving TRT, according to study findings presented at the Sexual Medicine Society of North America 18th Annual ...

and more » 


Repros Therapeutics (NASDAQ:RPRX) Experiences Heavier than Usual Trading Volume - Highlight Press



Repros Therapeutics (NASDAQ:RPRX) Experiences Heavier than Usual Trading Volume 
Highlight Press
Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. Through its clinical program, the Company is focused on conducting a Phase IIb study for low dose oral Proellex in the ...

and more » 


Male Hypogonadism Market 2022 Growth Forecast Analysis by ... - satPRnews (press release)



Male Hypogonadism Market 2022 Growth Forecast Analysis by ... 
satPRnews (press release)
Male Hypogonadism Market report gives the overall market outline to Male Hypogonadism Industry. The Male Hypogonadism market report investigations yearly ...

and more »